Literature DB >> 19471123

IDO recruits Tregs in melanoma.

George C Prendergast1, Richard Metz, Alexander J Muller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19471123     DOI： 10.4161/cc.8.12.8887

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  17 in total

1.  Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.

Authors:  Rikke Baek Sørensen; Sine Reker Hadrup; Inge Marie Svane; Mads Christian Hjortsø; Per Thor Straten; Mads Hald Andersen
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

Review 2.  Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology.

Authors:  Mads Hald Andersen
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer.

Authors:  Mads Duus Hjortsø; Stine Kiaer Larsen; Per Kongsted; Özcan Met; Thomas Mørch Frøsig; Gitte Holmen Andersen; Shamaila Munir Ahmad; Inge Marie Svane; Jürgen C Becker; Per Thor Straten; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2015-01-30       Impact factor: 8.110

Review 4.  Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.

Authors:  Juan R Cubillos-Ruiz; Melanie Rutkowski; Jose R Conejo-Garcia
Journal:  Cell Cycle       Date:  2010-01-26       Impact factor: 4.534

Review 5.  Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity.

Authors:  Tomoko Aoki; Naoshi Nishida; Masatoshi Kudo
Journal:  J Histochem Cytochem       Date:  2021-11-09       Impact factor: 2.479

Review 6.  The T-win® technology: immune-modulating vaccines.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2018-07-02       Impact factor: 9.623

7.  Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.

Authors:  Giuseppina Bonanno; Andrea Mariotti; Annabella Procoli; Valentina Folgiero; Daniela Natale; Luca De Rosa; Ignazio Majolino; Linda Novarese; Alberto Rocci; Manuela Gambella; Marilena Ciciarello; Giovanni Scambia; Antonio Palumbo; Franco Locatelli; Raimondo De Cristofaro; Sergio Rutella
Journal:  J Transl Med       Date:  2012-12-11       Impact factor: 5.531

Review 8.  The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase.

Authors:  Mads Hald Andersen
Journal:  Cancer Immunol Immunother       Date:  2012-03-03       Impact factor: 6.968

Review 9.  Lessons from cancer immunoediting in cutaneous melanoma.

Authors:  Mariana Aris; María Marcela Barrio; José Mordoh
Journal:  Clin Dev Immunol       Date:  2012-08-14

10.  Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.

Authors:  Derek A Wainwright; Alan L Chang; Mahua Dey; Irina V Balyasnikova; Chung Kwon Kim; Alex Tobias; Yu Cheng; Julius W Kim; Jian Qiao; Lingjiao Zhang; Yu Han; Maciej S Lesniak
Journal:  Clin Cancer Res       Date:  2014-04-01       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.